Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 234 results
Filters: First Letter Of Title is B  [Clear All Filters]
Found 234 results.

Adult

Palermo B, Bosch RJ, Bennett K, Jacobson JM. "Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy." HIV Clin Trials. 2011;12(4):222-7.
McComsey GA, Kitch D, Daar ES, et al. "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG." J. Infect. Dis.. 2011;203(12):1791-801.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. "Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection." J. Infect. Dis.. 2012;206(10):1558-67.
Reynolds NR, Neidig JL, Wu AW, Gifford AL, Holmes WC. "Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution." AIDS Care. 2006;18(7):663-73.
Hoffman RM, Jamieson BD, Bosch RJ, et al. "Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals." J. Clin. Immunol.. 2011;31(5):873-81.
Anthony DD, Conry SJ, Medvik K, et al. "Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection." J. Infect. Dis.. 2012;206(6):969-73.
Dumond JB, Rigdon J, Mollan K, et al. "Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results." J. Acquir. Immune Defic. Syndr.. 2015;70(5):510-4.
Brown TT, Chen Y, Currier JS, et al. "Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals." J. Acquir. Immune Defic. Syndr.. 2013;63(3):323-30.
Macatangay BJ, Yang M, Sun X, et al. "Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217." J. Acquir. Immune Defic. Syndr.. 2017;75(1):137-141.
Huang JS, Hughes MD, Riddler SA, Haubrich RH. "Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142." HIV Clin Trials. 2013;14(5):224-34.
Sax PE, Komarow L, Finkelman MA, et al. "Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia." Clin. Infect. Dis.. 2011;53(2):197-202.
Saberi P, Neilands TB, Vittinghoff E, Johnson MO, Chesney M, Cohn SE. "Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants." AIDS Patient Care STDS. 2015;29(3):111-6.

Anti-HIV Agents

Dumond JB, Rigdon J, Mollan K, et al. "Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results." J. Acquir. Immune Defic. Syndr.. 2015;70(5):510-4.
Lederman MM, Penn-Nicholson A, Cho M, Mosier D. "Biology of CCR5 and its role in HIV infection and treatment." JAMA. 2006;296(7):815-26.
Saberi P, Neilands TB, Vittinghoff E, Johnson MO, Chesney M, Cohn SE. "Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants." AIDS Patient Care STDS. 2015;29(3):111-6.
Halvas EK, Aldrovandi GM, Balfe P, et al. "Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency." J. Clin. Microbiol.. 2006;44(7):2612-4.
Huang JS, Hughes MD, Riddler SA, Haubrich RH. "Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142." HIV Clin Trials. 2013;14(5):224-34.
McComsey GA, Kitch D, Daar ES, et al. "Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG." J. Infect. Dis.. 2011;203(12):1791-801.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. "Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection." J. Infect. Dis.. 2012;206(10):1558-67.

Pages